IL241054A0 - Synthetic peptidoglycans that bind to extracellular matrix - Google Patents

Synthetic peptidoglycans that bind to extracellular matrix

Info

Publication number
IL241054A0
IL241054A0 IL241054A IL24105415A IL241054A0 IL 241054 A0 IL241054 A0 IL 241054A0 IL 241054 A IL241054 A IL 241054A IL 24105415 A IL24105415 A IL 24105415A IL 241054 A0 IL241054 A0 IL 241054A0
Authority
IL
Israel
Prior art keywords
extracellular matrix
binding synthetic
synthetic peptidoglycans
peptidoglycans
binding
Prior art date
Application number
IL241054A
Other languages
English (en)
Hebrew (he)
Original Assignee
Symic Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symic Biomedical Inc filed Critical Symic Biomedical Inc
Publication of IL241054A0 publication Critical patent/IL241054A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)
IL241054A 2013-03-15 2015-09-02 Synthetic peptidoglycans that bind to extracellular matrix IL241054A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798916P 2013-03-15 2013-03-15
PCT/US2014/029596 WO2014144969A1 (en) 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans

Publications (1)

Publication Number Publication Date
IL241054A0 true IL241054A0 (en) 2015-11-30

Family

ID=51537842

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241054A IL241054A0 (en) 2013-03-15 2015-09-02 Synthetic peptidoglycans that bind to extracellular matrix

Country Status (14)

Country Link
US (3) US9200039B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970509B1 (cg-RX-API-DMAC7.html)
JP (1) JP6603650B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150130419A (cg-RX-API-DMAC7.html)
AU (1) AU2014233537A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022917A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903450A1 (cg-RX-API-DMAC7.html)
EA (1) EA201591454A1 (cg-RX-API-DMAC7.html)
HK (1) HK1220217A1 (cg-RX-API-DMAC7.html)
IL (1) IL241054A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015012608A (cg-RX-API-DMAC7.html)
SG (1) SG11201506966RA (cg-RX-API-DMAC7.html)
WO (1) WO2014144969A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506391B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2280720T (lt) 2008-03-27 2019-07-25 Purdue Research Foundation Kolageną surišantys sintetiniai peptidoglikanai, jų paruošimas ir naudojimo būdai
PT2714718T (pt) 2011-05-24 2017-04-19 Symic Ip Llc Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico
EP2970509B1 (en) 2013-03-15 2020-05-13 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
WO2015175565A2 (en) 2014-05-12 2015-11-19 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
JP6693728B2 (ja) * 2014-11-14 2020-05-13 興和株式会社 新規な機能性ペプチド
WO2016100846A1 (en) 2014-12-19 2016-06-23 Northwestern University Thromboresistant-anticoagulant extracellular matrix
WO2016161333A2 (en) * 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
CN107771085B (zh) * 2015-04-17 2024-09-03 斯米克控股(美国)有限公司 生物缀合物及其用途
EP3294312B1 (en) * 2015-05-12 2020-07-08 Northwestern University Materials for tissue regeneration
EP3512561A4 (en) * 2016-09-16 2020-10-07 Glycologix, LLC SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMETICS
EP3648775A4 (en) * 2017-07-07 2021-04-21 Symic IP, LLC CHEMICALLY MODIFIED SKELETON BIOCONJUGATES
JP2020526497A (ja) 2017-07-07 2020-08-31 サイミック アイピー， エルエルシー 合成バイオコンジュゲート
WO2019010485A1 (en) * 2017-07-07 2019-01-10 Symic Ip, Llc TREATMENT OF FIBROSIS
WO2019075213A1 (en) 2017-10-11 2019-04-18 Northwestern University HEPARIN CONJUGATED TO PEPTIDES BINDING TO COLLAGEN FOR TARGETING BIOLOGICAL AND SYNTHETIC FABRICS
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors
EP4580751A2 (en) 2022-09-29 2025-07-09 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
CN119907690A (zh) * 2022-10-14 2025-04-29 国立大学法人东海国立大学机构 糖链复合体、药物载体和药物递送系统

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683298A (en) 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
US5547936A (en) 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
KR910700063A (ko) 1988-12-20 1991-03-13 알. 더글라스 암스트롱 상처 치료 활성을 갖는 폴리펩티드-고분자 결합체
US5693625A (en) 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
DE69230136T2 (de) 1991-01-14 2000-05-25 New York University, New York Cytokin-induziertes protein, tsg-6, seine dna und verwendung
JP2901787B2 (ja) 1991-07-15 1999-06-07 日本メジフィジックス株式会社 核磁気共鳴造影剤
FR2718023B1 (fr) 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
CA2239775C (en) 1995-12-18 2008-07-15 Collagen Corporation Crosslinked polymer compositions and methods for their use
CA2299687C (en) 1997-08-04 2009-10-27 Bio Syntech Ltd. Temperature-controlled ph-dependant formation of ionic polysaccharide gels
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
CA2307846A1 (en) 1997-11-21 1999-06-03 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7691829B2 (en) 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
JP3103531B2 (ja) 1998-09-30 2000-10-30 延也 柳内 ヒト尿由来細胞接着糖蛋白質及びその製造方法
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20110214206A1 (en) 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
FR2794976B1 (fr) 1999-06-16 2004-05-07 Solutions Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
WO2001019386A2 (en) 1999-09-15 2001-03-22 Dewoolfson Bruce H Composition for stabilizing corneal tissue during or after orthokeratology lens wear
FR2799465B1 (fr) 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
WO2001041822A1 (en) 1999-12-09 2001-06-14 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US20030158302A1 (en) 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
AU2001288392A1 (en) 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
AU2001286791A1 (en) 2000-08-31 2002-03-13 University Of Delaware Bioactive peptide for cell adhesion
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2002221370A1 (en) 2000-11-15 2002-05-27 Bio Syntech Canada Inc Method for restoring a damaged or degenerated intervertebral disc
WO2003029401A2 (en) 2001-07-13 2003-04-10 Advanced Research And Technology Institute Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
WO2003015615A2 (en) 2001-08-15 2003-02-27 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
ES2357889T3 (es) 2001-11-15 2011-05-03 Piramal Healthcare (Canada) Limited Composición y método para reticular o modificar homogéneamente quitosano en condiciones neutras.
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US20090158452A1 (en) 2001-12-04 2009-06-18 Johnson Richard G Transgenic plants with enhanced agronomic traits
WO2003075848A2 (en) 2002-03-08 2003-09-18 Zymogenetics, Inc. Inhibitors for use in hemostasis
US7666852B2 (en) 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
JP2005185101A (ja) 2002-05-30 2005-07-14 National Institute Of Agrobiological Sciences 植物の全長ｃＤＮＡおよびその利用
US7862831B2 (en) 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US8673333B2 (en) 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US20090183270A1 (en) 2002-10-02 2009-07-16 Adams Thomas R Transgenic plants with enhanced agronomic traits
JP2006501846A (ja) 2002-10-04 2006-01-19 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ローソニア・イントラセルラリス由来の核酸およびポリペプチド配列ならびに使用方法
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
FR2846659B1 (fr) 2002-10-30 2005-02-18 Centre Nat Rech Scient Fragments peptidiques du facteur harp inhibant l'angiogenese
AU2003294318A1 (en) 2002-11-15 2004-06-15 Arizona Board Of Regents Arizona State University Therapeutic bioconjugates
CA2523178C (en) 2003-03-24 2012-10-23 Luitpold Pharmaceuticals, Inc. Materials and methods to potentiate cancer treatment
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005041986A2 (fr) 2003-10-28 2005-05-12 Organes Tissus Regeneration Reparation Remplacement - Otr3 Utilisation de polymeres biocompatibles pour la preparation d'une composition ou d'un dispositif medical
FR2861308A1 (fr) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs
WO2005055800A2 (en) 2003-12-15 2005-06-23 Technion Research & Development Foundation Ltd. Therapeutic drug-eluting endoluminal covering
EP1722834B1 (en) 2003-12-22 2012-06-27 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US7709439B2 (en) 2004-02-20 2010-05-04 Boston Scientific Scimed, Inc. Biomaterials for enhanced healing
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
EP1758931A1 (en) 2004-05-31 2007-03-07 National University of Singapore Peptides derived from decorin leucine rich repeats and uses thereof
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
EP1796690A4 (en) 2004-09-22 2011-08-03 Cartilix Inc KNORPELFÜLLVORRICHTUNG
EP1804844A4 (en) 2004-09-29 2012-02-29 Univ Singapore COMPOSITE, PROCESS FOR ITS MANUFACTURE AND ITS APPLICATIONS
US20060241022A1 (en) 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates
WO2006047758A1 (en) 2004-10-27 2006-05-04 Massachusetts Institute Of Technology Novel technique to fabricate molded structures having a patterned porosity
US8283414B2 (en) 2004-11-23 2012-10-09 The Johns Hopkins University Compositions comprising modified collagen and uses therefor
EP1853278A4 (en) 2005-02-18 2011-12-28 Cartilix Inc MATERIALS COMPRISING GLUCOSAMINE
WO2006089119A2 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
JP2008531733A (ja) 2005-03-04 2008-08-14 ノースウエスタン ユニバーシティ 血管新生性のヘパリン結合エピトープ、ペプチド両親媒性物質、自己集合組成物、および関連する使用法
GB2424223C (en) 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
EP1863404A2 (en) 2005-03-30 2007-12-12 Cartilix, Inc. Coated medical device
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8367639B2 (en) 2005-03-31 2013-02-05 University Of Delaware Hydrogels with covalent and noncovalent crosslinks
US8415325B2 (en) 2005-03-31 2013-04-09 University Of Delaware Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels
US8338390B2 (en) 2005-03-31 2012-12-25 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US7737131B2 (en) 2005-03-31 2010-06-15 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US20070124833A1 (en) 2005-05-10 2007-05-31 Abad Mark S Genes and uses for plant improvement
US8044022B2 (en) 2005-06-08 2011-10-25 Tadeusz Kolodka Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
US20080069774A1 (en) 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
JP2009529374A (ja) 2006-03-07 2009-08-20 アクスル インターナショナル 治療及び癒着防止用生物活性スキャホールド
US20070212385A1 (en) 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
WO2007109069A2 (en) 2006-03-15 2007-09-27 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
AU2007299219A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20090162436A1 (en) 2006-06-14 2009-06-25 Carson Daniel D Compositions and methods for repair of tissues
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8114835B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles for tissue engineering
US8114834B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles
US20100222546A1 (en) 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
US20080295196A1 (en) 2006-12-06 2008-11-27 Abad Mark S Genes and uses for plant improvement
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
US9624259B2 (en) 2007-04-16 2017-04-18 Regentis Biomaterials Ltd. Compositions and methods for scaffold formation
US20100119577A1 (en) 2007-05-06 2010-05-13 Byoung-Hyun Min Therapeutic composite for cartilage disorder using extracellular matrix (ecm) scaffold
US20100191215A1 (en) 2007-06-12 2010-07-29 By-Pass ,Inc. Pressure pulse actuating device for delivery systems
US20090075281A1 (en) 2007-07-10 2009-03-19 Regents Of The University Of California Mtbe genes
US7993679B2 (en) 2007-09-25 2011-08-09 Integra Lifesciences Corporation Flowable wound matrix and its preparation and use
US20100210509A1 (en) 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
LT2280720T (lt) 2008-03-27 2019-07-25 Purdue Research Foundation Kolageną surišantys sintetiniai peptidoglikanai, jų paruošimas ir naudojimo būdai
KR101594552B1 (ko) 2008-04-04 2016-02-17 유니버시티 오브 유타 리서치 파운데이션 알킬화된 반합성 글리코사미노글리코산 에테르 및 이의 제조 및 사용 방법
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
US20100004196A1 (en) 2008-06-17 2010-01-07 Hopitaux Universitaires De Geneve Heparan sulfate proteoglycan composition and use thereof
WO2010011857A2 (en) 2008-07-23 2010-01-28 The Johns Hopkins University Parenteral administration of a glucosamine
US20110269208A1 (en) 2008-08-15 2011-11-03 The Trustees Of The University Of Pennsylvania Cross-linked polymer network formed by sequential cross-linking
US20130014292A1 (en) 2008-09-17 2013-01-10 Pennell Roger I Transgenic plants having increased biomass
FR2936247B1 (fr) 2008-09-24 2010-10-22 Ct Hospitalier Universitaire De Dijon Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire.
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8859706B2 (en) 2008-11-28 2014-10-14 Zetascience Gmbh Bioactive hydrogel
KR101062068B1 (ko) 2008-12-01 2011-09-02 포항공과대학교 산학협력단 유착방지용 조성물
IL195764A0 (en) 2008-12-07 2009-11-18 Technion Res & Dev Foundation Compositions and methods for drug delivery
WO2010083179A2 (en) 2009-01-16 2010-07-22 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
EP3070097A3 (en) 2009-03-30 2016-11-23 Nestec S.A. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
WO2010115156A2 (en) 2009-04-03 2010-10-07 Synthetic Genomics, Inc. Endophytic fungus and uses therefor
CA2758522A1 (en) 2009-04-13 2010-10-21 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
FI20095452A0 (fi) 2009-04-23 2009-04-23 Suomen Punainen Risti Veripalv Uudet haaraiset sokerianalyysit
US20120100106A1 (en) 2009-05-04 2012-04-26 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US20130052155A1 (en) 2009-11-09 2013-02-28 Drexel University Compositions and Methods for Treating a Disorder or Defect in Soft Tissue
US20130045926A1 (en) 2009-12-04 2013-02-21 Dale P. DeVore Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
CA2783000A1 (en) 2009-12-16 2011-06-23 Regentis Biomaterials Ltd. Scaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof
US20130035307A1 (en) 2010-01-26 2013-02-07 University Of Utah Research Foundation Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
EP3569241A1 (en) 2010-02-26 2019-11-20 Vascular Biosciences, Inc. Car peptide for homing, diagnosis & targeted therapy for pulmonary and fibrotic disorders
ES2742218T3 (es) 2010-06-23 2020-02-13 Purdue Research Foundation Peptidoglicanos sintéticos que se enlazan al colágeno destinados a ser utilizados en operaciones vasculares
WO2012112767A2 (en) 2011-02-16 2012-08-23 Purdue Research Foundation Collagen-targeted nanoparticles
US20130101628A1 (en) 2011-04-29 2013-04-25 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
PT2714718T (pt) 2011-05-24 2017-04-19 Symic Ip Llc Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico
US9795686B2 (en) 2012-01-19 2017-10-24 The Johns Hopkins University Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
WO2014038866A1 (ko) 2012-09-05 2014-03-13 아주대학교산학협력단 연골세포 유래 세포외 기질막을 이용한 신생혈관질환 치료용 조성물 및 각막 또는 결막 이식재
DE102012108560B4 (de) 2012-09-13 2018-12-20 Leibniz-Institut Für Polymerforschung Dresden E.V. Nichtkovalente selbstorganisierende Hydrogelmatrix für biotechnologische Anwendungen
WO2014063102A1 (en) 2012-10-19 2014-04-24 Cornell University Biomimetic boundary lubricants for articular cartilage
WO2014071132A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
EP2970509B1 (en) 2013-03-15 2020-05-13 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
WO2014171084A1 (ja) 2013-04-16 2014-10-23 パナソニックＩｐマネジメント株式会社 電力変換装置、電力変換方法、モータシステム、３相モータ
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
WO2015175565A2 (en) 2014-05-12 2015-11-19 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
WO2016061147A1 (en) 2014-10-13 2016-04-21 John Eric Paderi Luminal vessel coating for arteriovenous fistula
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
WO2016161333A2 (en) 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
CN107771085B (zh) 2015-04-17 2024-09-03 斯米克控股(美国)有限公司 生物缀合物及其用途
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate

Also Published As

Publication number Publication date
MX2015012608A (es) 2016-07-06
US20190022175A1 (en) 2019-01-24
ZA201506391B (en) 2017-09-27
KR20150130419A (ko) 2015-11-23
AU2014233537A1 (en) 2015-09-10
JP2016516065A (ja) 2016-06-02
US9872887B2 (en) 2018-01-23
US9200039B2 (en) 2015-12-01
US20160129076A1 (en) 2016-05-12
EP2970509A4 (en) 2016-11-02
HK1220217A1 (zh) 2017-04-28
EP2970509B1 (en) 2020-05-13
EA201591454A1 (ru) 2015-12-30
WO2014144969A1 (en) 2014-09-18
SG11201506966RA (en) 2015-10-29
BR112015022917A2 (pt) 2017-07-18
CA2903450A1 (en) 2014-09-18
EP2970509A1 (en) 2016-01-20
JP6603650B2 (ja) 2019-11-06
US20140288002A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
IL241054A0 (en) Synthetic peptidoglycans that bind to extracellular matrix
GB201317887D0 (en) Product
GB201305668D0 (en) Avs6 Integrin Antagonists
GB201413149D0 (en) No details
SG2013046479A (en) Bio-based synthetic fluids
GB201506699D0 (en) No details
GB201421649D0 (en) No details
GB201321785D0 (en) Route Monitoring
GB201410903D0 (en) No details
GB201418212D0 (en) No details
GB201416327D0 (en) No details
GB201421548D0 (en) No details
GB201408089D0 (en) No details
GB201418129D0 (en) No details
GB201418214D0 (en) No details
GB201312729D0 (en) Cleaning product
GB201407200D0 (en) No details
GB201302290D0 (en) Cleaning product
GB201417843D0 (en) No details
GB201420520D0 (en) No details
GB2530230B (en) Voltage-limiter monitoring
GB201311769D0 (en) Product
GB2509781B (en) Transmitter
GB201500998D0 (en) No details
GB201316462D0 (en) Creating reports